Drug intelligence / Profile preview

siRNA against pyk2

Development stage
Preclinical
Lead developer
Universidad Central del Caribe
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

siRNA against pyk2 refers to small interfering RNA molecules designed to silence the expression of Protein Tyrosine Kinase 2 beta (Pyk2), also known as PTK2B or focal adhesion kinase 2 (FAK2). Pyk2 is a non-receptor tyrosine kinase that plays a critical role in cellular processes such as migration, proliferation, and survival, particularly in the context of the tumor microenvironment. Research presented at AACR 2024 indicates that Pyk2 signaling is involved in the regulation of PD-L1 expression in glioblastoma (GBM) cells. The use of siRNA to knock down Pyk2 in primary human GBM cells resulted in a 50% decrease in PD-L1 expression, suggesting that Pyk2 is a viable therapeutic target for modulating immunosuppression in GBM and potentially enhancing the efficacy of immune checkpoint inhibitors.

Other names
Pyk2 siRNAPyk-2 siRNAPyk 2 siRNAPTK2B siRNAPTK-2B siRNAPTK 2B siRNAsiRNA-Pyk2siRNA-Pyk-2siRNA-Pyk 2
02

Targets

PTK2B

Beyond the preview

Go deeper on siRNA against pyk2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on siRNA against pyk2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call